Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu, Associate Professor and Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center. Together, they dive into the latest findings from ESMO 2024, focusing on key studies in lung cancer that every community oncologist should be aware of.

Episode Highlights:
•⁠ ⁠LAURA Trial: Discussing the role of osimertinib in locally advanced unresectable EGFR-mutant lung cancer post-chemoradiation and its impact on CNS progression-free survival.
•⁠ ⁠MARIPOSA and MARIPOSA-2 Studies: Exploring the importance of amivantamab in metastatic non-small cell lung cancer, including insights on resistance patterns and treatment sequencing.
•⁠ ⁠ADRIATIC Study: Analyzing the use of durvalumab as consolidation therapy in limited-stage small cell lung cancer and its implications for practice, including updates on prophylactic cranial irradiation (PCI).

Join us as we unpack these pivotal studies that are shaping the future of lung cancer treatment. Don't forget to check out our highlights on GI, GU, and breast cancer from ESMO 2024!

Subscribe for more insights and updates in oncology!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC